Most people expect that once breast cancer treatment is over, the risk of it coming back fades quickly with each passing year. For many types of breast cancer, that is broadly true. But for one common type, called hormone-receptor-positive breast cancer, the picture is a little different. The risk of it returning falls more slowly and can stay with a person for a very long time, sometimes 15 or 20 years after the original diagnosis. Doctors call this late recurrence.
If you or someone you love has had hormone-positive breast cancer, hearing this can feel unsettling. It is meant to be the opposite. Understanding why this happens, and what your treatment team does about it, can help replace vague worry with clear facts. This article explains, in plain English, what late recurrence is, what the research tells us, and what it means for your follow-up care.
This is general, educational information, not personal medical advice. Your own situation is unique. If you have questions or symptoms that worry you, please speak to your GP, breast care nurse or treatment team, who know your history and can give you advice based on you.
What hormone-receptor-positive breast cancer means
Breast cancers are tested in the laboratory to see what makes them grow. According to Cancer Research UK, many breast cancers have receptors that pick up the hormone oestrogen, and sometimes progesterone, and use it as fuel. These are called hormone-receptor-positive cancers, often shortened to ER-positive (oestrogen-receptor-positive) or HR-positive. It is the most common type of breast cancer.
Because these cancers feed on hormones, they can often be treated with hormone therapy, also called endocrine therapy. The NHS explains that these are tablets or injections, such as tamoxifen or a group of drugs called aromatase inhibitors, that lower oestrogen or block its effect. They are usually taken for several years after surgery, chemotherapy or radiotherapy to lower the chance of the cancer returning.
Why hormone-positive cancer can come back late
The key idea behind late recurrence is something called dormancy. Cancer Research UK explains that, in some people, a small number of cancer cells can break away from the original tumour and travel to other parts of the body before treatment begins. Treatment removes or kills the cancer that doctors can see and find. But a few of these stray cells can survive by going into a kind of deep sleep, where they stop dividing and growing.
This sleeping state is the heart of the puzzle. Most cancer treatments, including chemotherapy, work best on cells that are actively dividing. According to Cancer Research UK, dormant cells are not dividing, so they can slip past many treatments and survive for years without causing any harm or showing up on scans. Then, sometimes after a very long time, something can wake them up and they begin to grow again. When this happens, the cancer can return, either near where it started or in another part of the body.
Scientists are still working to understand exactly what keeps these cells asleep and what wakes them. Cancer Research UK notes that dormancy seems to depend on signals from the surrounding cells and tissue, and on changes in how cells read their genes. Understanding this better is one of the big goals of current breast cancer research, because finding a way to keep dormant cells asleep, or to clear them safely, could help prevent late recurrence altogether.
What the research shows about the risk over time
A large body of research, brought together by the Early Breast Cancer Trialists' Collaborative Group and published in the New England Journal of Medicine, followed almost 63,000 women with ER-positive breast cancer who had completed five years of hormone therapy and were free of cancer at that point. It then tracked what happened over the years from year 5 to year 20 after diagnosis.
The study found that the risk of the cancer spreading to another part of the body continued steadily, year after year, all the way out to 20 years from diagnosis. In other words, the danger did not simply disappear after five years. Importantly, the level of risk varied a lot from person to person, depending mainly on the size of the original tumour and how many lymph nodes were affected.
- For women with a small tumour and no affected lymph nodes, the chance of the cancer spreading between year 5 and year 20 was roughly 1 in 10 to around 1 in 8.
- For women with larger tumours or several affected lymph nodes, the risk over the same period was higher, in some groups reaching around 4 in 10.
- Across the groups, recurrences kept happening at a fairly steady pace throughout the whole period, rather than all at once.
These figures describe large groups of people studied over many years. They cannot tell any single person what will happen to them. They are useful because they explain why your team thinks about your care over a long horizon, and why features like tumour size and lymph nodes matter so much when planning follow-up and treatment.
How treatment helps lower late recurrence
The good news is that hormone therapy is one of the most effective ways to reduce this long-term risk. According to the NHS and Cancer Research UK, taking hormone therapy after treatment lowers the chance of hormone-positive breast cancer coming back, and the benefit continues even after you stop taking it.
Because the risk lasts a long time, researchers have studied whether taking hormone therapy for longer helps further. Cancer Research UK explains that, for some people, continuing hormone therapy beyond the usual five years, often up to around ten years in total, can lower the risk of late recurrence further. This is not right for everyone, because the tablets can have side effects, and the extra benefit is larger for some people than others. Whether to continue is a careful, personal decision made with your treatment team, weighing the possible benefit against the side effects and how you are feeling.
If you find hormone therapy hard to keep taking because of side effects, you are not alone, and it is worth telling your team rather than stopping on your own. There are often ways to help, such as changing to a different drug, adjusting the dose or managing specific side effects. Because these tablets work over years, taking them as prescribed is one of the most powerful things within your control.
What late recurrence means for your follow-up
Because hormone-positive breast cancer can return late, follow-up care is planned with the long term in mind. The NHS explains that after treatment you usually have regular check-ups and surveillance mammograms, which are breast X-rays designed to spot any change early. The exact timetable depends on your hospital and your situation, but follow-up often continues for several years, and surveillance mammograms may carry on for longer.
Between appointments, the most important thing is to know your own body and to report any new or lasting changes rather than waiting for the next scheduled visit. According to Cancer Research UK, changes worth mentioning to your team include:
- A new lump or thickening in the breast, chest area or armpit.
- Changes to the skin of the breast or to the nipple.
- Bone pain that does not go away, or a new ache that is unexplained.
- A lasting cough or breathlessness, ongoing tiredness, or unexplained weight loss.
- Any symptom that is new, persistent or simply not normal for you.
Most aches, pains and everyday illnesses are not a sign that cancer has returned, and worrying about every twinge is exhausting. The aim is not to live on high alert, but to have a low threshold for getting new and lasting changes checked. If something does not settle within a couple of weeks, contact your GP or breast care nurse. Getting checked early is reassuring far more often than not, and if anything does need attention, finding it sooner gives the best chance to act.
It is also completely normal to feel anxious about recurrence, especially around check-ups or scan results. This feeling is common enough to have a name, fear of recurrence, and there is real support available for it, from your breast care nurse to counselling and charity helplines. You do not have to carry that worry alone.
Why this matters for everyone, everywhere
The whole picture of late recurrence rests on one foundation: being able to find, test and treat breast cancer properly in the first place, and then to follow up over many years. According to the World Health Organization, access to early diagnosis and good treatment is uneven, and many people in underserved and low-income communities are diagnosed late or cannot reach the long-term care that hormone-positive cancer needs.
This is central to our charity's mission. By supporting early detection and better access to care in underserved communities, we want more people to begin treatment sooner and to stay connected to the follow-up that helps catch any late return early. Clear, trustworthy information like this is part of that work, because understanding your care is the first step to taking part in it.
If you take one thing from this article, let it be this: late recurrence is a known, studied part of hormone-positive breast cancer, and your treatment team plans for it. Long-term hormone therapy and follow-up exist precisely because of it. Keep taking your treatment as prescribed, attend your check-ups, report lasting changes, and lean on your team and the support around you. You are not expected to manage any of this alone.
Share this article